Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sunshine Biopharma Inc. (NASDAQ: SBFM) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Sunshine Biopharma’s pharmaceutical and biotechnology operations, corporate governance, and financial reporting, complementing its public news releases about generics, biosimilars, and proprietary drug development.
Investors can review current reports on Form 8-K, where Sunshine Biopharma reports material events. Recent 8-K filings describe matters such as the dismissal of Bush & Associates CPA LLC as the company’s independent registered public accounting firm, the engagement of M&K CPAS, PLLC as its new auditor, and the outcomes of the annual meeting of stockholders. The December 2025 Form 8-K, for example, details the election of directors, ratification of M&K CPAS, PLLC for the 2025 audit year, and stockholder approval of an amendment to the 2023 Equity Incentive Plan to increase the number of shares authorized for issuance.
The platform also surfaces Sunshine Biopharma’s Definitive Proxy Statements on Schedule 14A, which outline proposals submitted to shareholders, board composition, corporate governance practices, executive compensation information, and procedures for the annual meeting. These filings help readers understand how the company is managed and how key decisions—such as equity incentive plan changes or auditor selection—are presented to and approved by shareholders.
On Stock Titan, Sunshine Biopharma’s 10-K annual reports, 10-Q quarterly reports, proxy statements, and 8-K current reports are supplemented with AI-powered summaries that explain complex sections in plain language. Users can quickly identify disclosures related to revenue sources, generic and biosimilar activities, research and development commitments, auditor changes, and equity incentive plans without reading every page. Real-time updates from EDGAR ensure that new filings, including any future Forms 4 reporting insider transactions, appear promptly, while AI-generated highlights point to sections that may be most relevant for analysis.
By using this filings page, investors, analysts, and researchers can efficiently review Sunshine Biopharma’s regulatory history, track governance and accounting developments, and connect formal SEC disclosures with the company’s broader strategy in generics, biosimilars, mRNA cancer therapies, and antiviral drug development.
Sunshine Biopharma Inc. reported 2025 revenue of $36,305,891, up from $34,874,283 in 2024, driven mainly by expanded Canadian generic drug sales through its Nora Pharma subsidiary. Cost of sales was $24,050,214, yielding gross profit of $12,255,677.
The company remains unprofitable, recording a 2025 net loss of $5,975,352 and an accumulated deficit of $75,015,126, though operating cash use declined versus 2024. Sunshine ended 2025 with $9,123,308 in cash and believes this will fund operations for about 18 months. Its portfolio includes 71 generic drugs in Canada, 22 pipeline generics, OTC supplements, and two proprietary programs (K1.1 mRNA for liver cancer and SBFM-PL4, a PLpro inhibitor for SARS coronavirus) in animal testing. In December 2025 it received a USPTO Notice of Allowance for its coronavirus protease inhibitor patent, and it holds trademarks for “Sunshine Biopharma Inc.” in the U.S. and Canada.
Sunshine Biopharma Inc. notified the SEC on Form 12b-25 that its Form 10-K for the period ended December 31, 2025 could not be filed on time due to time constraints in compiling, disseminating and reviewing required information. The company states it will file the Form 10-K no later than fifteen days after the original prescribed due date.
The notification was signed by Dr. Steve N. Slilaty, Chief Executive Officer on March 31, 2026. A contact phone number is provided for follow-up.
Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. is informing holders that on February 18, 2026 the majority stockholder approved an amendment authorizing the Board to effect, at its discretion, a reverse stock split of up to 1-for-10. The Board may set any whole-number ratio up to 1-for-10 or abandon the action prior to filing.
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of February 18, 2026, there were 4,905,945 shares outstanding; a 1-for-10 split would reduce outstanding shares to 490,595, subject to rounding.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. notified holders that the holder of approximately 96.4% voting power, Dr. Steve N. Slilaty, approved by written consent an amendment to permit a reverse stock split of the common stock by a ratio of up to 1-for-10, with the Board having sole discretion whether to implement the split and to set the exact whole-number ratio up to 1-for-10.
As of February 18, 2026, the company had 4,905,945 shares outstanding; at a 1-for-10 split that figure would become 490,595 shares (fractional shares rounded up). The stated purpose is to address Nasdaq’s $1.00 minimum bid-price requirement; effectiveness requires filing the amendment with the Colorado Secretary of State.
Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.
Sunshine Biopharma Inc. reported the results of its annual stockholder meeting held on December 11, 2025. Stockholders elected five directors — including Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller — to serve until the next annual meeting or until successors are elected and qualified.
Shareholders also ratified the appointment of M&K CPAS, PLLC as the company’s independent registered public accounting firm for 2025. In addition, they approved an amendment to the 2023 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan to 683,000, providing additional equity available for future employee and director compensation awards.
Sunshine Biopharma (SBFM) filed its Q3 2025 10‑Q, highlighting year‑over‑year revenue growth and a smaller quarterly loss. Revenue for the quarter reached $9,417,179, up 11.6% from a year ago, with gross profit of $3,073,540. Operating loss was $1,086,613, and net loss narrowed to $883,820, or $0.19 per share.
For the nine months ended September 30, 2025, revenue was $27,728,750 (up 9.7%). Net loss for the period was $3,834,425, reflecting higher G&A and a $1,616,459 impairment of intangible assets tied to product licenses that could not be commercialized. Cash and equivalents were $9,306,438 as of September 30, 2025.
The company completed an April 2025 registered direct offering, receiving $1,828,596 in net proceeds, and reported additional cash from warrant exercises during the year. Shares outstanding were 4,555,945 as of September 30, 2025, and 4,905,945 as of November 13, 2025. Management aims to reduce cost of goods sold toward 60% to move toward breakeven while continuing to expand Nora Pharma’s Canadian generic portfolio.
Sunshine Biopharma (SBFM) will hold its 2025 virtual annual meeting on December 11, 2025 to vote on three items: elect five directors, ratify M&K CPAS, PLLC as auditor, and amend the 2023 Equity Incentive Plan to increase shares authorized for issuance from 1,661 to 683,000.
The record date is October 17, 2025, with 4,905,945 common shares and 130,000 Series B Preferred outstanding. Each Series B Preferred share carries 1,000 votes, and all Series B shares are held by the CEO, concentrating voting power. The Board recommends voting FOR all proposals.
Auditor history was addressed: following the SEC’s settled order permanently barring BF Borgers from practicing before the SEC, the company dismissed Borgers in 2024, engaged Bush & Associates, and on September 24, 2025 appointed M&K CPAS, PLLC. Executive agreements disclose severance terms, including $14,000,000 for the CEO upon certain terminations. Pay-versus-performance data shows 2024 net loss of $(5,134,116) and a total shareholder return of (99.9%) based on a $1.00 investment benchmark.